Can a 13-year-old male receive the Adacel (Tdap) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Adacel can be given to a 13-year-old male

Adacel (Tdap) is approved and recommended for adolescents aged 11-18 years, making a 13-year-old male an appropriate candidate for this vaccine. 1

Licensing and Age Approval

The FDA has licensed Adacel for use in individuals aged 10 through 64 years 2. Specifically, while Boostrix (the other Tdap vaccine) is approved starting at age 10, Adacel is approved beginning at age 11 1, 3, 1. Since your patient is 13 years old, he falls well within the approved age range for Adacel administration.

ACIP Recommendations for Adolescents

The Advisory Committee on Immunization Practices (ACIP) provides clear guidance:

  • Adolescents aged 11-18 years should receive a single dose of Tdap instead of Td for booster immunization if they have completed the recommended childhood DTP/DTaP vaccination series and have not previously received Td or Tdap 4

  • The preferred age for Tdap vaccination is 11-12 years, but adolescents aged 13-18 years who missed the 11-12 year dose should receive a single dose of Tdap if they completed the childhood DTP/DTaP series 1

  • Either Tdap product (Boostrix or Adacel) can be administered to adolescents regardless of the type or manufacturer of pediatric DTP/DTaP used for childhood vaccination 4

Administration Details

  • Dose: 0.5 mL administered intramuscularly (IM), preferably into the deltoid muscle 4

  • Timing: If the patient previously received Td, an interval of at least 5 years between Td and Tdap is encouraged to reduce local and systemic reactions. However, an interval less than 5 years can be used when the benefit of pertussis protection outweighs the risk of reactions 4

  • Co-administration: Tdap can be administered simultaneously with other vaccines indicated for this age group (such as meningococcal conjugate vaccine MCV4) during the same visit, using separate syringes at different anatomic sites 4

Important Safety Considerations

Monitor for syncope: Fainting can occur after vaccination and is more common among adolescents and young adults. Consider a 15-20 minute observation period following vaccination 4. If syncope occurs, observe until symptoms resolve.

Common side effects include pain, redness and swelling at the injection site, headache, body ache, tiredness, and fever 2.

Contraindications to Verify

Before administering Adacel, ensure the patient does NOT have:

  • History of serious allergic reaction (anaphylaxis) to any component of the vaccine or previous tetanus, diphtheria, or pertussis vaccine 3, 2
  • History of encephalopathy within 7 days of a previous pertussis vaccine dose not attributable to another cause 3, 2

The evidence strongly supports administering Adacel to this 13-year-old male, as he is within the approved age range and falls into the recommended catch-up vaccination group for adolescents who may have missed their 11-12 year Tdap dose.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.